er abstract competitor shionogi result continu
support select approach although tast effect
less expect
abstract european respiratori societi er releas weekend includ phase ii
result placebo-control japanes studi shionogi select antagonist
previous announc test patient demonstr reduct
awak cough frequenc daili cough frequenc
respect compar placebo refer reduct compar phase
iib studi merck nyse gefapix new inform abstract
overal incid treatment-emerg advers event significantli differ
two treatment specif tast chang tast injuri observ
treatment mg dose test question remain
around pk/pd tast effect dose use prior studi said
tast effect less expect includ us pertain bellu toronto blu
blu thought abstract follow
result support key driver chronic cough good exact
role inhibit result tast alter cough arent known yet given
limit data select antagonist appear none low
given similar efficaci seen less select gefapix tast effect detail
data continu suggest low-to-no effect tast loss given prior
data enhanc select vs vs estim
howev also mean may bigger competitor previous
thought particularli sinc dose once/day vs twice/day note bellu
manag believ formul once-daili version given properti
although independ verifi possibl
base kol feedback report tast effect may report compar
multi-n studi due cultur reason dig verifi contact us
detail drug dose typic lower japan us eu variou reason
link link region may use higher dose tast effect could
pronounc upcom multi-national dose-rang studi shed
light await guidanc dose test
once/day dose clearli prefer twice/day although physician spoke believ
price overal profil drug affect uptak note chronic cough unlik
winner take market importantli bellu current posit come market prior
shionogi also impact uptak
base bellu recent financ adjust price target
depend result er may revisit model/assumpt
mid phase ii result chronic cough
begin phase ii studi chronic pruritu associ atop
year left
financi cad
analyst certif disclosur pleas see page
tast data date remind select vs compar merck gefapix
advanc antagonist develop chronic cough phase iii on-going phase studi
one subject report tast alter expect therapeut dose bid significantli better seen
gefapix figur incid tast alter common higher dose like coincid degre inhibit
receptor commonli found tast bud
figur indirect comparison tast gefapix
phase ii data provid clariti rel profil bellu enrol patient random
placebo-control phase ii dose-escal crossov trial relief assess safeti efficaci
unexplained/refractori chronic cough patient across trial site us uk four dose level bid
select antagonist test escal interv studi monitor awak cough frequenc similar
endpoint use gefapix phase iib studi cough frequenc prefer regulatori bodi addit patient
undergo two-week screen period follow-up period determin cough frequenc pre- post-treat top-lin result studi
anticip provid import inform treatment posit chronic cough market
chronic cough larg market room multipl player multipl expert emphas chronic cough
debilit diseas underappreci gener commun diseas take substanti toll patient physic social
psycholog perspect addit fatigu chest pain headach nausea femal patient make
total patient popul also experi urinari incontin given lack novel approv therapi last fifti year refractory/
idiopath chronic cough remain area high unmet need outsid non-pharmacolog therapi like speech patholog behavior therapi
physician left prescrib opiat benzonat neuromodul pregabalin/gabapentin associ meaning
dextromethorphan shown consist efficaci
market chronic cough may larger model indic bellu recent kol day bluestar bioadvisor third-parti consult
group review market analysi estim primari address chronic cough patient diagnos
year inclus criteria clinic trial also note secondari patient diagnos greater
eight week less one year one expert mention clear pathophysiolog differ two patient popul
investor day merck also estim global chronic cough preval refractori idiopath true
larger estim use model bluestar bioadvisor merck anticip mani restrict payer
enforc label
twelve-month price target base dcf valuat assum wacc termin growth rate million fulli dilut
share pro-forma po best-in-class antagonist potenti upsid model includ better expect
clinic result could requir us boost peak penetr probabl success relev indic expans
addit indic potenti success earlier anticip regulatori approv sale surpass
expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg
initi target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
lifesci capit lsc research analyst denot ac cover report certifi multipl research analyst primarili
respons report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur reflect
person view subject secur subject compani part research analyst compens
directli indirectli relat specif recommend view express research analyst report
